Results 41 to 50 of about 2,116 (170)

Anti-inflammatory and biologic drugs for atopic dermatitis: a therapeutic approach in children and adolescents

Frontiers in Medicine, 2023
Atopic dermatitis (AD) is a chronic inflammatory disease with a heterogeneous pathogenesis correlated with dysregulation of the immune system and a prevalence of the T2-mediated immune pathway.
Carlo Caffarelli, Arianna Giannetti, Giuliana Giannì, Giampaolo Ricci   +3 more
doaj   +1 more source

Tralokinumab for moderate-to-severe UC: a randomised, double-blind, placebo-controlled, phase IIa study

, 2015
International audienceOBJECTIVE:Interleukin-13 (IL-13) has been implicated as a key driver of UC. This trial evaluates the efficacy and safety of tralokinumab, an IL-13-neutralising antibody, as add-on therapy in adults with moderate-to-severe UC despite
Uebel, Peter, Brandt, Wolfgang, Hansen, Mark Berner, Rudziński, Janusz, Knutsson, Mikael, Dupas, Jean-Louis, Lukas, Milan, Danese, Silvio, Bouhnik, Yoram, Keshav, Satish, Kleczkowski, Dariusz, Peyrin-Biroulet, Laurent, Erlandsson, Fredrik   +12 more
core   +1 more source

Efficacy and Safety of Tralokinumab in Adolescents With Moderate to Severe Atopic Dermatitis: The Phase 3 ECZTRA 6 Randomized Clinical Trial [PDF]

, 2023
IMPORTANCE: Safe and effective long-term treatments for adolescents with moderate to severe atopic dermatitis (AD) are limited. OBJECTIVE: To evaluate the efficacy and safety of interleukin-13-targeted treatment with tralokinumab monotherapy in ...
Eric L. Simpson, Petra Arlert, Blauvelt, Andrew, Andreas Wollenberg, Wollenberg, Andreas, Shinichi Imafuku, Katja Wendicke Lophaven, Schuttelaar, Marie L A, H. Chih-ho Hong, Paller, Amy S, Andrew Blauvelt, Schuttelaar, Marie L A; id_orcid, Weily Soong, Marie L. A. Schuttelaar, Imafuku, Shinichi, Lise Soldbro, Lophaven, Katja Wendicke, Natacha Strange Vest, Soong, Weily, Simpson, Eric L, Flohr, Carsten, Azra Kurbasic, Carsten Flohr, Kurbasic, Azra, Vest, Natacha Strange, Anthony Bewley, Arlert, Petra, Amy S. Paller, Cork, Michael, Bewley, Anthony, Soldbro, Lise, Michael Cork, Hong, H Chih-Ho   +32 more
core   +2 more sources

A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma

, 2013
Pre-clinical data demonstrate a pivotal role for interleukin (IL)-13 in the development and maintenance of asthma. This study assessed the effects of tralokinumab, an investigational human IL-13-neutralising immunoglobulin G4 monoclonal antibody, in ...
Piper, Edward, Brightling, Christopher, Molfino, Nestor A., Oh, Chad, She, Dewei, Niven, Robert, Faggioni, Raffaella, Poon, Kwai, Kell, Chris, May, Richard D., Geba, Gregory P.   +10 more
core   +1 more source

Tralokinumab for the treatment of severe, uncontrolled asthma: the ATMOSPHERE clinical development program

, 2018
Tralokinumab, a fully human IgG4 monoclonal antibody, specifically neutralizes IL-13. The ATMOSPHERE clinical development program comprised four randomized, placebo-controlled clinical trials and an open-label study that aimed to assess the efficacy and
Millie Wang, Karin Bowen, Gene Colice, Reynold A Panettieri Jr, Martin Braddock   +4 more
core   +1 more source

Peripheral ulcerative keratitis associated with tralokinumab therapy: a case report and review of IL-13 inhibitor-associated ocular surface disease

Journal of Ophthalmic Inflammation and Infection
Background Dupilumab and tralokinumab are interleukin-binding monoclonal antibodies used to treat systemic atopic disease. Use of these medications in management of atopic dermatitis (AD) is known to cause conjunctivitis.
Nenita Maganti, Samuel A. Whittier, Evan J. Warner   +2 more
doaj   +1 more source

The Tralokinumab Pre-Filled Pen Improved Atopic Dermatitis Signs and Symptoms and Was Well Tolerated in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: A 16-Week, Open-Label, Single-Arm Phase 3 Study (INJECZTRA)

Dermatology and Therapy
Introduction The tralokinumab pre-filled pen was developed to improve patient convenience and deliver 300 mg tralokinumab (the recommended dose for most patients) with one injection.
Jennifer Soung, Vivian Laquer, Matthew Zirwas, Peter van Iperen, John C. Stinson, Katrine Lykke Albertsen, Linda Stein Gold   +6 more
doaj   +1 more source

Health-related quality of life with tralokinumab in moderate-to-severe atopic dermatitis: A phase 2b randomized study

, 2021
Background: Atopic dermatitis (AD) is associated with a substantial burden on quality of life (QoL). Objective: To evaluate the effects of tralokinumab on health-related QoL in patients with moderate-to-severe AD using patient-reported outcomes. Methods:
Gooderham, Melinda, Guttman-Yassky, Emma, Rippon, Stephanie, O\u27Quinn, Sean, Kurbasic, Azra, Kragh, Nana, van der Merwe, René, Wollenberg, Andreas, Worm, Margitta, Silverberg, Jonathan I.   +9 more
core   +1 more source

Tralokinumab did not demonstrate oral corticosteroid-sparing effects in severe asthma

, 2019
Long-term oral corticosteroid (OCS) use in patients with severe asthma is associated with significant adverse effects. This 40-week, randomised, double-blind trial evaluated the OCS-sparing potential of tralokinumab in patients with severe, uncontrolled
Korn, Stephanie, Wang, Millie M., Kuna, Piotr, Cohen, David, Brusselle, Guy, Busse, William W, Busse, William, Magnan, Antoine, Piechowiak, Teresa, Bowen, Karin, Colice, Gene, Wang, Millie M   +11 more
core   +1 more source

Comparative Efficacy and Safety of Monoclonal Antibodies and Janus Kinase Inhibitors in Moderate-to-severe Atopic Dermatitis: A Systematic Review and Meta-analysis

Acta Dermato-Venereologica, 2022
The aim of this study was to compare the efficacies of systemic treatments with dupilumab, tralokinumab and Janus kinase inhibitors for moderate-to-severe atopic dermatitis. A systematic review following Preferred Reporting Items for Systemic Reviews and
Farnam B. Sedeh, Mattias A.S. Henning, Gregor B.E. Jemec, Kristina S. Ibler   +3 more
doaj   +1 more source